For those considering treatment with a checkpoint inhibitor

We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …

Advances in the identification of patients who may respond well to particular types of immunotherapy

A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer. … READ MORE …

A thorough review of immunotherapeutics in the treatment of prostate cancer

A new review article has just been published in the journal Critical Reviews in Hematology Oncology. It is probably a current “must read” for support group leaders and for any patients who are interested in the idea of using immunotherapy as a treatment for progressive and advanced forms of prostate cancer. … READ MORE …

The “hyping” of new forms of treatment for cancer

In a newly published article on the STAT web site, two clinicians at Oregon Health and Science University argue that the benefits of immunotherapy in the treatment of cancer are being greatly over-“hyped”. … READ MORE …

The ASCO Genitourinary Cancers Symposium: a brief report

Your sitemaster is gradually “coming back to life” after a rather unpleasant week that included his trip to the GU Cancers Symposium (when he should probably have been in his bed at home). So here is the quick summary from Orlando. … READ MORE …

Immunotherapy for the treatment of prostate cancer

The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …